Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

CompletedOBSERVATIONAL
Enrollment

402

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

August 12, 2019

Study Completion Date

December 6, 2019

Conditions
Diabetic Retinopathy
Interventions
DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY